GE Healthcare announced that it has signed a multi-year strategic agreement with United Pharmacy Partners, Inc (UPPI). The result of this contract is that GE will provide positron emission tomography (PET) radiopharmacy technology, including PETtrace cyclotron and TRACERlabPET chemistry platform used for the production of PET radiopharmaceuticals, to UPPI members across the United States.
Established in 1998, UPPI is a leader in traditional nuclear medicine and in the rapidly growing nuclear and PET pharmacy industries, with more than 70 operating sites of independently owned nuclear pharmacies throughout the country. Currently, UPPI members have PETtrace cyclotrons in 13 radiopharmacy institutions across the U.S., and they anticipate continued growth in membership.
UPPI President Perry Polsinellia says that they forecast that this strategic agreement will support their leadership in nuclear medicine and specifically in PET. "The adoption of PET as a diagnostic tool and the increasing demand from our customers for greater access will enable our continued growth in the market."